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β-Glucocerebrosidase (GBA) is the enzyme that degrades glucosylceramide in lyso-
somes. Defects in GBA that result in overall loss of enzymatic activity give rise to the
lysosomal storage disorder Gaucher disease, which is characterized by the accumula-
tion of glucosylceramide in tissue macrophages. Gaucher disease is currently treated
by infusion of mannose receptor-targeted recombinant GBA. The recombinant GBA
is thought to reach the lysosomes of macrophages, based on the impressive clinical
response that is observed in Gaucher patients (type 1) receiving this enzyme replace-
ment therapy. In this study, we used cyclophellitol-derived activity-based probes
(ABPs) with a fluorescent reporter that irreversibly bind to the catalytic pocket of
GBA, to visualize the active enzymes in a correlative microscopy approach. The
uptake of pre-labeled recombinant enzyme was monitored by fluorescence and elec-
tron microscopy in human fibroblasts that stably expressed the mannose receptor.
The endogenous active enzyme was simultaneously visualized by in situ labeling with
the ABP containing an orthogonal fluorophore. This method revealed the efficient
delivery of recombinant GBA to lysosomal target compartments that contained
endogenous active enzyme.
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1 | INTRODUCTION
The lysosomal acid β-glucosidase, β-glucocerebrosidase (GBA, EC
3.2.1.45), is essential to the catabolism of glycosphingolipids in
lysosomes as it removes the β-D-glucopyranose group from
glucosylceramide. The enzyme encoded by the GBA gene is synthe-
sized as a 497 amino acid protein in the endoplasmic reticulum. While
the majority of the lysosomal enzymes are modified with the mannose
6-phosphate recognition marker to mediate their transport from the
biosynthetic pathway to the lysosomes, GBA does not contain phos-
phomannosyl residues.1–3 Instead, GBA is routed via a mannose
6-phosphate independent targeting pathway, by binding to the lyso-
somal membrane protein, LIMP II.4 LIMP II interacts with newly syn-
thesized GBA at the site of the endoplasmic reticulum. After passage
through the Golgi complex, the LIMP II-GBA complex is directed to
endosomes and lysosomes, likely through a dileucine-based sorting
Received: 26 September 2018 Revised and accepted: 19 March 2019
DOI: 10.1111/tra.12641
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. Traffic published by John Wiley & Sons Ltd.
346 wileyonlinelibrary.com/journal/tra Traffic. 2019;20:346–356.
motif in its C-terminal cytosolic tail.5,6 The importance of LIMP II is
evident as individuals with LIMP II deficiency develop progressive
myoclonic epilepsy with glomerulosclerosis and neurological manifes-
tations, named action myoclonus-renal failure syndrome (AMRF).7,8 In
AMRF, mutations in the SCARB2 gene encoding LIMP II cause the fail-
ure of normally synthesized GBA to interact with LIMP II. As a result,
GBA is secreted from the cells, leading to reduced lysosomal levels of
the enzyme in various cell types.4,7,9,10
Mutations in GBA result in a prominent loss of GBA in
lysosomes and cause the autosomal recessive lysosomal storage dis-
order Gaucher disease.11 Gaucher disease is characterized by the
accumulation of the substrate glucosylceramide in tissue macro-
phages.12 The clinical manifestations of the disease are remarkably
variable, but usually include enlargement of the liver and spleen,
infiltration of the bone marrow by storage macrophages, thrombo-
cytopenia, anemia and bone disease, and can include neurological
symptoms. Currently approved treatments are substrate reduction
therapy aiming to reduce substrate buildup in macrophages and
enzyme replacement therapy (ERT), in which human recombinant
GBA (hrGBA) is administered intravenously. To mediate uptake by
macrophages, hrGBA is modified to expose its mannose moieties,
which bind to the mannose receptor (Man-R) present at the surface
of these cells. Endocytosis of the Man-R delivers hrGBA to the
endo-lysosomal system.
The development of activity-based probes (ABPs) that covalently
and irreversibly tag GBA with high sensitivity and almost complete
selectivity has allowed the ultra-sensitive visualization of active GBA
molecules in vitro and in vivo in cells and organisms.13 These
cyclophellitol-derived ABPs react with the catalytic nucleophile
Glu340 of GBA to form an enzyme-substrate complex, linked
through an ester bond that is stable under native physiological con-
ditions. When applied to the cell culture medium, the ABPs rapidly
enter the cells, a process that appears independent of
endocytosis,13 and bind to the intracellular pools of GBA. The pres-
ence of a fluorescent reporter allows the detection by light micros-
copy.13 As fluorescence microscopy does not provide information
about the underlying ultrastructure, in this study a correlative light
and electron microscopy (CLEM) approach was employed to allow
the more detailed localization of active GBA. Moreover, the cellular
fate of hrGBA following binding to the Man-R was investigated. The
uptake of ABP-prelabeled hrGBA was monitored while simulta-
neously visualizing the endogenous enzyme by using ABPs with dif-
ferent fluorescent reporters. Light microscopy showed colocalization
of endocytosed and endogenous GBA, but also distinct punctae for
either endocytosed or endogenous enzyme. By CLEM, the endoge-
nous GBA was mainly localized to lysosomes, where it showed sub-
stantial overlap with endocytosed hrGBA. Of note, some lysosomes
did not appear to be reached by hrGBA during the course of the
experiment. In addition, the endocytosed enzyme was detected in
earlier compartments of the endo-lysosomal system that showed no
detectable endogenous GBA. This method will be valuable in deter-
mining the efficiency of ERT for Gaucher disease and potentially
other lysosomal storage diseases.
2 | RESULTS
GBA was readily detected in normal human dermal fibroblasts
(NHDFs) by fluorescence microscopy upon in situ labeling with the
ABP, MDW941 (Figure 1), consistent with previous observations by
our lab.13 Under these conditions, approximately 50% of total GBA
was labeled, as determined by GBA activity assays. Pre-incubation
with conduritol B epoxide (CBE) for 16 hours prior to the in situ label-
ing with MDW941, which should block the active site of all available
GBA molecules,14 resulted in no detectable signal (Figure S1 in Data
S1), neither was any signal detected upon dimethyl sulfoxide (DMSO)
or CBE incubation in the absence of probe (Figure S1in Data S1).
These data indicate that the fluorescent signal does not represent
unbound, endocytosed probe and is specific to active GBA. Impor-
tantly, in situ labeled GBA showed clear overlap with total GBA as
detected by confocal immunofluorescence microscopy after staining
with antibodies to GBA (Figure 1, upper panels, Figure S2A in Data
S1). Significant overlap was also detected with the late
endosomal/lysosomal marker LAMP-1, although not all LAMP-1 con-
taining compartments appeared positive for GBA (Figure 1, lower
panels, Figure S2A in Data S1). Loading of the late compartments of
the endo-lysosomal system with the endocytic tracer fluorescein iso-
thiocyanate (FITC)-dextran (3 hours pulse, 6 hours chase), resulted in
substantial colocalization with MDW941, although not all MDW941
positive punctae contained dextran (Figure S3 in Data S1).
To identify the endo-lysosomal compartments that accumulated
active GBA, a correlative microscopy approach was applied. First,
GBA was in situ labeled as in the previous experiments, after which
the cells were fixed, gelatin embedded and prepared for electron
microscopy according to the Tokuyasu technique.15 The ultrathin
cryosections on grids were first mounted on glass slides with 50%
glycerol to allow their imaging by confocal microscopy. This revealed
the presence of numerous fluorescent punctae per cell profile
(Figure 2A). Subsequently, the sections were contrasted and embed-
ded with uranyl acetate/methylcellulose and imaged with an electron
microscope. Overlay of the fluorescent images and electron micro-
graphs showed that most of the fluorescent signal localized to
membrane-bound compartments (Figure 2B,C), while the CBE-pre-
treated and DMSO-treated sections showed no fluorescent signal.
The membrane-bound compartments mainly represented lysosomes,
as identified by the presence of the characteristic internal membrane
sheets and their electron dense appearance (Figure 2D,E). The earlier
compartments of the endo-lysosomal system, the endosomes, charac-
terized by their more electron lucent appearance and intraluminal ves-
icles and the absence of internal membrane sheets, occasionally
showed low levels of active GBA, but in most cases the signal was
below the detection limit (Figure 2D,E). These data indicate that the
majority of the active GBA molecules in fibroblasts reside in the
lysosomes.
To allow the efficient internalization of hrGBA by human fibro-
blasts, cell lines were generated that stably express the mannose
receptor (Man-R) with a C-terminal V5 tag. In this way, the uptake of
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hrGBA by the modified fibroblasts mimics the mode of uptake by tis-
sue macrophages, which express Man-R at their surface. Fibroblasts
that were obtained from a patient homozygous for the nonsense
mutation p.W178X7 contained no detectable levels of LIMP II by
Western blotting (Figure 3A). As a result, the intracellular level of GBA
was significantly reduced. In control fibroblasts, three bands were
detected for GBA by Western blotting (Figure 3A), that is, the com-
plex glycosylated form, the ER form and the late endosomal/lysosomal
form.16 In the LIMP II−/− cells low levels of the ER form were detected
(Figure 3A) and the intracellular GBA activity was reduced to approxi-
mately 5 ± 0.9% of the level in control fibroblasts (Figure 3B). These
findings are consistent with the absence of the lysosomal targeting
receptor LIMP II, which results in the increased secretion of GBA by
these cells. Lentiviral transduction of both NHDFs and LIMP II−/−
fibroblasts with MRC1 resulted in the expression of the Man-R as
determined by anti-V5 immunoblotting (Figure 3A) and immunofluo-
rescence microscopy (Figure S4 in Data S1), with the LIMP II−/− cells
containing slightly higher expression levels of Man-R than the
NHDFs.
Subsequently, hrGBA was in vitro labeled with MDW933 (an ABP
functionalized with a green fluorescent BODIPY dye13) and, after the
removal of unreacted ABP (Figure S5 in Data S1), added to the culture
medium to follow its uptake in the various cell lines. A 6 hours-
incubation with MDW933-hrGBA resulted in the enhanced
internalization of hrGBA by fibroblasts that expressed the Man-R,
both NHDFs and LIMP II−/−, as compared to those that did not
express the receptor (Figure 3C). Somewhat higher levels of hrGBA
were observed in the LIMP II−/− cells as compared to the NHDFs,
which is likely because of the higher levels of Man-R present in the
former, resulting in increased uptake. Competition with mannan, to
block the Man-R, reduced the uptake to the same level in all cell lines.
This level likely reflects the uptake by fluid-phase endocytosis. The
effect of mannan that was observed in NHDFs and LIMP II−/− fibro-
blasts that did not overexpress the Man-R might be caused by the
block of another lectin responsible for hrGBA internalization, as these
cells are unlikely to express the Man-R endogenously.
To visualize the delivery of hrGBA to the intracellular target com-
partments and find out whether it reaches the lysosomes that contain
active GBA, MDW933-labeled hrGBA was applied to the culture
medium of the four different cell lines, while endogenous GBA was
labeled simultaneously with MDW941. Analysis by SDS-PAGE
showed labeling of the endogenous enzyme with the red probe in
NHDFs, identified as two bands representing the complex glyco-
sylated and lysosomal forms of GBA (Figure 4). In LIMP II−/− fibro-
blasts the GBA levels were in most instances too low to be detected
by this method (Figure 4). Importantly, uptake of MDW933-labeled
hrGBA did not result in significant cross-labeling of the endogenous
enzyme because of unreacted MDW933, as only a single band was
F IGURE 1 Active GBA accumulates in late endosomes and lysosomes. In situ labeling of active GBA in NHDFs with 5 nM MDW941 for
2 hours shows a punctate staining pattern (red) by confocal fluorescence microscopy. Significant overlap is observed with total GBA (green, see
arrows in insets upper panels) and the late endosomal/lysosomal marker LAMP-1 (green, see arrows in insets lower panels) upon immunostaining
with specific antibodies. The arrowheads show LAMP-1 positive compartments that contain no detectable levels of MDW941. Nuclei were
stained with DAPI (blue). Scale bars, 25 μm
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labeled with MDW933, representing hrGBA. In addition, the signal for
MDW941 had a similar intensity in the lanes with or without
MDW933-hrGBA. Likewise, no cross-labeling of internalized hrGBA
with MDW941 appeared to occur.
Subsequently, the same experimental set-up was used in confocal
fluorescence microscopy. The Man-R expressing cells represented a
heterogeneous population, as they expressed varying levels of recep-
tor. While the signal for MDW933-labeled hrGBA was below the
detection level in all cells without Man-R, a punctate staining pattern
was observed in NHDFs that expressed sufficient levels of Man-R
(Figure 5, upper panels). These punctae significantly overlapped with
endogenous GBA as visualized with MDW941, suggesting the deliv-
ery of hrGBA to lysosomes. However, some punctae were mainly pos-
itive for either hrGBA or endogenous GBA (see insets Figure 5,
Figure S2B in Data S1). A similar result was observed in NHDFs that
were immunostained for LAMP-1 after the 6 hours-uptake with
hrGBA (Figure S6 in Data S1). There was partial overlap of hrGBA and
LAMP-1. Importantly, no signal for MDW933-hrGBA could be visual-
ized after uptake in the presence of mannan, which further suggests
that no cross-labeling of endogenous GBA occurred with MDW933.
As expected, endogenous GBA failed to be detected in the LIMP II−/−
fibroblasts (Figure 5, middle panels). However, uptake of
MDW933-labeled hrGBA resulted in a punctate pattern that showed
partial overlap with LAMP-1 (Figure 5, lower panels, see insets,
Figure S2B in Data S1). These data suggest that hrGBA is delivered to
late endosomes/lysosomes in the absence of LIMP II.
With CLEM the nature of the various fluorescent punctae could
be identified. The uptake of labeled hrGBA was continuous for
6 hours, as shorter incubations did not result in sufficient levels of
internalized hrGBA that were detectable by our CLEM method. We
anticipated that the hrGBA-containing punctae would represent both
early and late compartments of the endo-lysosomal system. Consis-
tent with this prediction, hrGBA was present in endosomes, as well as
in lysosomes (Figure 6A-E). In addition, significant overlap was
observed between endocytosed and endogenous GBA in lysosomes
(Figure 6E). Interestingly, some lysosomes appeared to be negative for
endocytosed hrGBA (Figure 6E). In agreement with the previous data,
no endogenous GBA was detected by CLEM in the LIMP II−/− fibro-
blasts. However, endocytosed hrGBA was delivered to the endo-
somes and lysosomes (Figure 7), suggesting that the absence of LIMP
II does not have a major effect on the lysosomal delivery of GBA upon
endocytosis.
3 | DISCUSSION
In this study we have presented a correlative microscopy method that
combines the use of ABPs, for the detection of active lysosomal
enzyme by fluorescence microscopy, with electron microscopy. This
F IGURE 2 Correlative microscopy
shows the accumulation of active GBA
in lysosomes of NHDFs. A, Confocal
fluorescence image of an ultrathin
cryosection of NHDFs in situ labeled
with MDW941 for 2 hours at 5 nM.
The red punctae represent active GBA
(MDW941), while the blue dots
represent fluorescent electron dense
beads used for correlation of the
images. Scale bar, 10 μm. Merged
fluorescence and electron microscopy
images of boxed areas 1 and 2 are
shown in (B) and (C), respectively. Scale
bars, 3 μm. D, E, Magnifications of
boxed areas in (B) and (C), respectively.
MDW941 (red), which labels active
GBA, is present in lysosomes. E,
endosome; L, lysosome; M,
mitochondrion; PM, plasma membrane;
*, bead used for correlation. The white
arrowheads indicate lysosomes positive
for MDW941, recognized by the
internal membrane sheets, while the
black arrowheads indicate endosomes
negative for the ABP. Scale bars, D,
250 nm; E, 500 nm
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allows the visualization of the positive structures at high resolution.
The cyclophellitol-derived ABPs that irreversibly bind to the active
site of the lysosomal β-glucosidase GBA, readily penetrate through
the cellular membranes, which provides the great benefit that they
can be applied to living cells.13 In our approach, in situ labeling of
human fibroblasts with ABP, equipped with a fluorescent tag, was
followed by fixation and sample preparation according to the
Tokuyasu technique.15,17 The ultrathin cryosections were directly
imaged for their fluorescent signal by confocal microscopy, without
the need of on-section labeling reactions that could increase
background signals or influence the sensitivity of detection. The sub-
sequent imaging by electron microscopy provides a relatively straight-
forward technique to localize the active enzyme to distinct subcellular
compartments.
This correlative approach to localize GBA resulted in the detection
of active enzyme mainly in lysosomes. By confocal fluorescence
microscopy, the ABP colocalized well with our antibody to GBA and
was blocked by pre-incubation with the inhibitor CBE, showing the
specificity of GBA labeling. In addition, the ABP colocalized signifi-
cantly with the lysosomal membrane protein LAMP-1, which is
F IGURE 3 Man-R expressing fibroblasts endocytose increased amounts of MDW933-labeled hrGBA. A, NHDFs and LIMP II−/− fibroblast
lysates with or without Man-R with a V5-tag were subjected to SDS-PAGE and immunoblotting. No detectable levels of LIMP II are present in
the LIMP II−/− cells, while the levels of GBA are significantly reduced (lane 3 and 4). The Man-R is expressed in the control and LIMP II−/−
fibroblast lines (lane 2 and 4), as detected with an antibody to the V5 tag. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) shows equal
protein loading. B, GBA activity in the various cell lines as determined with 4-methylumbelliferyl-coupled specific substrate. The values are
averages of three independent experiments ± SDs, with the activity in NHDFs set to 100%. The activity in LIMP II−/− fibroblast lines is
approximately 5% of NHDFs, while the Man-R expressing NHDFs show a somewhat increased activity. * P < 0.01. C, Representative wet slab gel
of at least three independent experiments shows the increased uptake of hrGBA by Man-R expressing NHDFs and LIMP II−/− fibroblasts, as
compared to the Man-R negative fibroblasts. The addition of mannan reduces the hrGBA uptake to the same levels in all four cell lines, likely
representing the uptake by non-specific, fluid-phase endocytosis. 1% of total MDW933-hrGBA that was added to the culture medium (input) was
loaded for comparison. β-tubulin shows equal protein loading
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present in late endosomes and lysosomes.18,19 By CLEM we were able
to determine that the highest levels of active GBA were present in
lysosomes, based on the morphological characteristics of these com-
partments, while endosomes mostly appeared negative. Thus the
LAMP-1-containing, ABP-negative compartments most likely repre-
sent late endosomes with GBA levels below the detection limit.
Subsequently, we aimed to follow the uptake of recombinant GBA
and relate it to the localization of the endogenous enzyme using two-
color CLEM. To this end, hrGBA was in vitro labeled with ABP con-
taining a green fluorophore, while the endogenous pool of GBA was
in situ labeled with a red ABP. By confocal fluorescence microscopy
we observed a significant overlap of green and red fluorescent signals,
while there were also punctae positive for either fluorophore. Correla-
tive microscopy showed that the overlapping green/red signals mainly
localized to lysosomes, while the green dots represented endosomes
containing hrGBA and the red dots lysosomes that had not been
reached by endocytosed hrGBA. The observation that many, but not
all lysosomes were reached by endocytosed hrGBA could be a techni-
cality because of the imaging of sections instead of intact cells, or
other factors such as the duration of uptake. Alternatively, an
interesting possibility could be that there are different populations of
lysosomes, some more and others less accessible by endocytosis.
Altogether, the imaging of GBA with ABPs in this correlative
microscopy approach resulted in the localization of the enzyme to
specific subcellular compartments, without the need for additional
labeling.20,21 This method could be applied to model organisms as
well, as these ABPs can be delivered to various tissues upon intrave-
nous or intracerebroventricular injection in rodents.13,22 Moreover,
correction of lysosomal enzyme deficiency by ERT is presently pur-
sued for several other lysosomal storage disorders, such as Fabry dis-
ease and Pompe disease, which are caused by deficiency of lysosomal
α-galactosidase A (GLA) and lysosomal α-glucosidase (GAA),
respectively.23–25 As ABPs have already been designed for GLA and
GAA,26,27 this method might be applied to analyze the targeting of
these expensive drugs. Finally, mutations in GBA have recently been
recognized as a risk factor for multiple myeloma and carriers of one
mutant GBA allele are more likely to develop Parkinsonism and Lewy
body dementia.28,29 Extending our knowledge of this enzyme could
be instrumental to the understanding of these, and possibly other,
pathologies.
4 | MATERIALS AND METHODS
4.1 | Cell lines
Normal human dermal fibroblasts (NHDFs) were obtained from Lonza
and LIMP II−/− fibroblasts from a patient homozygous for the muta-
tion c.533G>A, resulting in an early stop codon at W178.7 All cell lines
were maintained in Dulbecco's Modified Eagle's Medium with 4.5 g/L
glucose, sodium pyruvate and sodium bicarbonate (D6546, Sigma),
supplemented with 10% (v/v) fetal bovine serum, 100 000 units/L
penicillin, 100 mg/L streptomycin and 2 mM glutamax (Thermo Fisher
Scientific Inc.) at 37C in a 5% CO2 humidified incubator.
NHDFs or LIMP II−/− fibroblasts stably expressing the mannose
receptor (Man-R) were generated by lentiviral transduction. Human
spleen mRNA was used to amplify the human MRC1 (MRC1,
NM_002438.3) coding sequence by polymerase chain reaction using
the following oligonucleotides: sense 50-GGG GAC AAG TTT GTA
CAA AAA AGC AGG CTT CGG TAC CAC CAT GAG GCT ACC CCT
GC -30 and antisense 50-GGG GAC CAC TTT GTA CAA GAA AGC
TGG GTC GAT GAC CGA GTG TTC ATT CTG -30. The fragment was
cloned into pDNOR-221, and subsequently sub-cloned into pLe-
nti6.3/TO/V5-DEST using the Gateway system (Invitrogen), generat-
ing a C-terminal V5 fusion protein. Because of toxicity of the
construct in E. coli CopyCutter EPI400 chemically competent E. coli
cells were used according to the manufacturer's protocol (Epicentre).
The full sequence was verified by DNA sequencing.
To produce lentiviral particles, HEK293T cells in 6-well plates
were transfected at approximately 70% confluency with the envelope
and packaging plasmids pMD2.G, pRSV, pMDL-RRE and
pLENTI6.3-MRC1 at a 1:1 ratio, 3 μg DNA in total, and 9 μg poly-
ethylenimine (PEI 25 K, Polysciences Inc.). The culture medium was
replaced 16 hours after transfection with culture medium containing
F IGURE 4 Simultaneous uptake of ABP-labeled hrGBA and
labeling of the active endogenous enzyme. The four different
fibroblast cell lines were allowed to take up 2 μg/mL
MDW933-hrGBA for 6 hours, while endogenous GBA was in situ
labeled during the final 2 hours with MDW941. A representative wet
slab gel shows endocytosed hrGBA (upper panel, scanned green
channel MDW933) and labeled endogenous GBA (middle panel,
scanned red channel MDW941). The lower panel shows the overlay
of the two channels. While endogenous GBA is readily detected in
NHDFs, the signal is too low in LIMP II−/− fibroblasts. β-tubulin shows
equal protein loading
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20 mM HEPES and collected twice after a 24 hours incubation period.
The culture medium containing viral particles was passed over a
0.45 μm filter and applied to the control and LIMP II−/− fibroblast lines
for 8-24 hours. Transduced cells were selected for by incubation with
2.5 μg/mL blasticidin (Sigma) containing culture medium for several
weeks.
4.2 | In situ labeling of GBA and fluorescence
microscopy
Cells were grown to approximately 70% confluency on glass cover-
slips in 12-well plates. GBA was in situ labeled by adding MDW941
(“red,” BODIPY 573/612) to the culture medium at a concentration of
F IGURE 5 Endocytosed hrGBA partially colocalizes with active GBA and LAMP-1. Confocal fluorescence microscopy of NHDFs and LIMP
II−/− fibroblasts expressing the Man-R after a 6 hours uptake of 2 μg/mL MDW933-hrGBA (green) and 2 hours in situ labeling of endogenous
GBA (red) with 5 nM MDW941 (upper and middle panels) or immunofluorescent staining of LAMP-1 (red, lower panels; see also Figure S6 in
Data S1 for LAMP-1 staining in NHDFs). Substantial colocalization was observed in NHDFs between endocytosed hrGBA and endogenous GBA
(see arrows in inset upper panels). In LIMP II−/− fibroblasts, the endocytosed enzyme reached a portion of the LAMP-1 positive compartments
(arrows in inset lower panels). The arrowheads indicate compartments positive for either endocytosed hrGBA or endogenous GBA/LAMP-1.
Scale bars, 10 μm
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5 nM. The cells were incubated for 2 hours in a humidified incubator
at 37C with 5% CO2. Pre-incubation with CBE (Enzo Life Sciences
Inc.) was performed at a concentration of 0.3 mM for 16 hours.
Unlabeled cells were incubated with similar percentages (v/v) of
DMSO. Uptake with FITC-CM-dextran (MW 70 000, Sigma) was per-
formed at a concentration of 1 mg/mL for 3 hours (pulse). Subse-
quently, the cells were washed five times with PBS and incubated in
culture medium for 6 hours (chase). In situ labeling with 5 nM
MDW941 was performed during the last 2 hours of the chase.
At the end of the incubations, the cells were washed three
times with PBS and fixed with 4% (w/v) formaldehyde (Sigma)/PBS
for 30 minutes at room temperature. After the fixation, the cells
were washed with PBS and distilled H2O, after which they were
either stained for immunofluorescence microscopy or mounted
directly on a microscope slide with ProLong Diamond antifade
reagent containing DAPI (Molecular Probes). Immunofluorescence
staining was performed as described.30 Antibodies used were
mouse anti-GBA monoclonal (8E4, generated in the Aerts lab) at
dilution 1:500, rabbit anti-LAMP-1 (Abcam) at dilution 1:400,
mouse anti-V5 (Invitrogen) at dilution 1:250 and Alexa Fluor conju-
gated IgGs (H + L) donkey anti-mouse Alexa 488 and donkey anti-
rabbit Alexa 488 (Invitrogen). The cells were imaged under a Leica
TCS SP8 confocal microscope with a 63×/1.40 numerical aperture
(NA) HC Plan Apo CS2 oil immersion objective and equipped with a
hybrid detector (HyD).
4.3 | In vitro labeling of hrGBA with MDW933
hrGBA (Cerezyme) was a kind gift from Genzyme. Five microliter
hrGBA at a concentration of 1 μg/μL was incubated for 16 hours at
37C with 40 μL of 150 mM McIlvaine buffer pH = 5.2, 0.2% (w/v)
sodium taurocholate (Calbiochem), 0.1% (v/v) Triton X-100 and 2 μM
MDW933 (“green,” BODIPY 493/503), while protected from the light.
After the incubation, an aliquot was kept to confirm that the residual
F IGURE 6 hrGBA is delivered to GBA-containing lysosomes in NHDFs as determined by CLEM. A-E, Overlay of electron micrograph and
confocal fluorescence image of an ultrathin cryosection of NHDFs expressing the Man-R. The cells were allowed to take up MDW933-labeled
hrGBA (green) for 6 hours, while endogenous GBA was labeled by adding MDW941 to the culture medium at a concentration of 5 nM for
2 hours (red). Nuclei were stained with DAPI (blue). Scale bar in A, 1 μm. B-D, Magnification of boxed area 1 from A. E, endosome; L, lysosome.
The arrow indicates an endosome that contains endocytosed hrGBA (green). E, Magnification of boxed area 2 from A showing lysosomes with
both endocytosed hrGBA (green) and endogenous GBA (red). One lysosome (arrow) contains mainly the endogenous enzyme. M, mitochondrion;
PM, plasma membrane. Scale bar, 500 nm
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hrGBA activity was reduced >99% (see below). The remainder was
passed over a protein desalting spin column, MWCO 7 K (Thermo Sci-
entific) according to the manufacturer's protocol, to remove any
unreacted probe (see also Figure S3 in Data S1).
4.4 | GBA activity assay
The enzymatic activity of hrGBA preparations or GBA in cell lysates
was measured by incubating 10-20 μL sample with 100 μL substrate
mix, which consisted of 3.75 mM 4-methylumbelliferyl β-D-
glucopyranoside (Glycosynth Limited), 0.2% (w/v) sodium
taurocholate (Calbiochem), 0.1% (w/v) BSA, 0.1% (v/v) Triton X-100
in 150 mM McIlvaine buffer pH = 5.2, in a 96-well plate at 37C. The
reactions were stopped with 200 μL 1 M glycine-NaOH pH = 10.3
and read in an LS55 fluorescence spectrometer (PerkinElmer) at λex
366 nm, λem 445 nm.
4.5 | Uptake of MDW933-labeled hrGBA and in situ
labeling of endogenous GBA
All uptake experiments were performed with 2 μg/mL
MDW933-labeled hrGBA for 6 hours. When indicated, MDW941 was
added during the last 2 hours of the incubation at a concentration of
5 nM. To block uptake of hrGBA by the Man-R, mannan from Saccha-
romyces cerevisiae (Sigma) was added simultaneously at 3 mg/mL. At
the end of the incubations, the cells were washed three times with
PBS and either lysed (for the GBA activity assay/SDS-PAGE) or fixed
for microscopy.
4.6 | SDS-PAGE and Western blotting
Cells were lysed by the addition of ice-cold lysis buffer, that is,
25 mM potassium phosphate buffer pH = 6.5, 0.1% Triton X-100 and
a protease inhibitor cocktail (cOmplete, Roche Diagnostics GmbH).
Total protein concentration in the lysates was determined by the
bicinchoninic acid (BCA) protein assay (Pierce BCA protein assay kit;
Thermo Fisher Scientific Inc.) in a 96-well plate format, according to
the manufacturer's protocol. The samples were read in an EMax Plus
microplate reader (Molecular Devices). Equal protein amounts (5 μg)
were resolved on 10% polyacrylamide gels and transferred onto
0.2 μm nitrocellulose membranes (Amersham, GE Healthcare).
Antibodies used were rabbit anti-LIMP II (Novus Biologicals), mouse
anti-GBA (8E4, generated in the Aerts lab), rabbit anti-GAPDH (Cell
Signaling), mouse anti-V5 (Invitrogen) and rabbit anti-β-tubulin (Cell Sig-
naling) and secondary antibodies used were donkey anti-rabbit Alexa
Fluor 647 IgG (H + L) (Invitrogen), goat anti-mouse IgG (H + L)-HRP
conjugate and goat anti-rabbit IgG (H + L)-HRP conjugate (BioRad).
Horseradish peroxidase (HRP)-conjugated antibodies were visualized
by chemiluminescence (Pierce ECL Plus Western blotting substrate,
Thermo Fisher Scientific Inc.). The wet slab gels and immunoblots were
scanned on a Typhoon FLA 9500 scanner (GE Healthcare).
4.7 | Correlative microscopy
NHDFs were grown in 100 mm culture dishes to approximately 70%
confluency. GBA was in situ labeled with 5 nM MDW941 for 2 hours
at 37C, either with or without pre-incubation with 0.3 mM CBE for
16 hours as a control for the specificity of the signal. To check for
autofluorescence, one dish was incubated for 2 hours with a similar
F IGURE 7 hrGBA is delivered to
lysosomes in LIMP II−/− fibroblasts as
determined by CLEM. A, B, Overlay of
electron micrograph and confocal
fluorescent image of an ultrathin
cryosection showing LIMP II−/−
fibroblasts + Man-R, after a 6 hours-
uptake of MDW933-labeled hrGBA
(green) and in situ labeling of
endogenous GBA (red, not detected).
Nuclei were stained with DAPI (blue).
Both endosomes (E) and lysosomes
(L) are positive for hrGBA, however,
not all of them are reached (arrows). M,
mitochondrion; *, bead used for
correlation. Scale bars, 500 nm
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percentage (v/v) of DMSO. The uptake experiments were performed
with NHDFs + Man-R and LIMP II−/− fibroblasts + Man-R, with
2 μg/mL MDW933-labeled hrGBA for 6 hours. During the last 2 hours
endogenous GBA was in situ labeled with 5 nM MDW941. As a con-
trol for the Man-R-specific uptake of MDW933-hrGBA, the uptake in
NHDFs + Man-R, followed by the in situ labeling was performed in
the presence of 3 mg/mL mannan.
At the end of the incubations, the culture medium was removed
and the cells were washed three times quickly with culture medium at
37C. Subsequently, the cells were fixed with 2% (w/v) formaldehyde
+0.2% glutaraldehyde (Electron Microscopy Sciences) in 0.1 M PHEM
buffer for 2 hours at room temperature, while protected from the
light. Embedding of the samples and cryosectioning was performed as
described.15 For correlation purposes, fluospheres carboxylate-
modified microspheres blue (350/440) with a diameter of 100 nm
(Thermo Fisher Scientific Inc.) were added to the grids, which were
coated with a formvar film, either before or after collection of the sec-
tions by incubating the grids for 2 minutes on the beads (1:2000 dilu-
tion of 2% solids). Subsequently, the sections were incubated on 2%
gelatin for 30 minutes at 37C and on 15 mM glycine/PBS for
10 minutes at room temperature. The nuclei were stained with
50 ng/mL DAPI (Sigma)/PBS for 5 minutes. After a quick wash with
distilled H2O, the ultrathin cryosections on titanium grids (Agar Scien-
tific) were mounted on microscope glass slides in 50% glycerol/H2O
and imaged under a Leica TCS SP8 confocal microscope with a
63×/1.40 NA HC Plan Apo CS2 oil immersion objective. Immediately
after imaging, the glycerol was removed from the grids by washing in
distilled H2O. The sections were contrasted with 1.8% methylcellu-
lose/0.6% uranyl acetate/H2O at pH = 4.8 and analyzed in a FEI
Tecnai 12 BioTwin electron microscope at 120 kV. Correlation of the
images was performed using Adobe Photoshop CC 2015.5.
4.8 | Labeling specificity in correlative microscopy
The specificity of the green and red fluorescent signals for hrGBA and
endogenous GBA, respectively, was determined in the following way.
First of all, the in vitro labeling reaction was optimized to label over
99% of hrGBA, which was confirmed by an enzymatic activity assay
to result in near absence of hrGBA activity. In this way, cross-labeling
of hrGBA with red ABP was prevented during the in situ labeling.
Consistent herewith, no red ABP signal was detected in fibroblasts
that lack GBA, because of a mutation in the receptor LIMP II, upon
endocytosis of labeled hrGBA. Secondly, any unreacted green ABP
was removed from the preparation before addition to the culture
medium. SDS-PAGE analysis showed substantial reduction of
unreacted ABP. Any remaining unreacted probe was not sufficient to
result in detectable cross-labeling of endogenous GBA as determined
by SDS-PAGE of the cell lysates. Finally, the uptake of ABP-labeled
hrGBA in the presence of mannan did not result in a detectable green
fluorescent signal in the cells by microscopy, indicating that the
endogenous enzyme was not labeled with green probe.
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